Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis Pharmaceuticals Corporation announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

21 Jul 2011

Nuvilex to move International Corporate HQ near FDA headquarters

Nuvilex, Inc. announced today it is in the final stages of locating its International Corporate Headquarters near the headquarters of the U.S. Food and Drug Administration.

15 Jul 2011

Men more likely to succumb to cancer

According to a new analysis of 36 different types of tumors and blood cancers that affect both sexes, men are more likely than women to get and die of cancer. The report shows that leukemia and cancers of the colon and rectum, pancreas, and liver killed about one and a half to two times as many men as women in the U.S. over a 30-year period. Lung cancer killed nearly two and a half times as many men during that time. According to the American Cancer Society men have about a 1 in 2 chance of developing cancer at some point in their lives, compared with women, who have a 1 in 3 chance.

13 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

Two defective genes may cause telomere elongations in cancer cells: Study

Scientists at Johns Hopkins have provided more clues to one of the least understood phenomena in some cancers: why the "ends caps" of cellular DNA, called telomeres, lengthen instead of shorten.

1 Jul 2011

Nuvilex to continue development of acquired live-cell encapsulation technology

Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.

29 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

Novel vaccine approach for prostate cancer

Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments.

20 Jun 2011

Pancreatic Cancer Action Network calls on federal government to make research a national priority

The Pancreatic Cancer Action Network is calling on the federal government to make pancreatic cancer research a national priority, as the incidence and death rates for the fourth leading cause of cancer death in our country continue to increase according to "Cancer Facts & Figures 2011," a report released today by the American Cancer Society.

18 Jun 2011

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. described today potential advantages of cell encapsulation technology for use in cancer therapies when more than one cancer-fighting drug is used.

17 Jun 2011

Nuvilex to acquire live cell encapsulation technology for multiple cancer therapies

Nuvilex, Inc. announced today it has entered into discussions to acquire the next generation live cell encapsulation technology that serves as the platform for multiple cancer therapies.

15 Jun 2011

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

Pancreatic Cancer News and Research

Further Reading

Adamis' APC-300 inhibits growth of prostate cancer cells

Nuvilex to move International Corporate HQ near FDA headquarters

Men more likely to succumb to cancer

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Six new scientists to receive SWCRF grants for cancer research

Two defective genes may cause telomere elongations in cancer cells: Study

Nuvilex to continue development of acquired live-cell encapsulation technology

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

Novel vaccine approach for prostate cancer

Pancreatic Cancer Action Network calls on federal government to make research a national priority

Nuvilex describes advantages of cell encapsulation technology for multiple cancer therapies

Nuvilex to acquire live cell encapsulation technology for multiple cancer therapies

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News